Index NDX, S&P 500
P/E -
EPS (ttm) -7.34
Insider Own 0.50%
Shs Outstand 159.00M
Perf Week 2.43%
Market Cap 19.70B
Forward P/E 50.70
EPS next Y 2.45
Insider Trans 0.89%
Shs Float 158.10M
Perf Month -2.94%
Income -1161.00M
PEG -
EPS next Q 0.04
Inst Own 93.55%
Short Float 3.34%
Perf Quarter -14.92%
Sales 4.50B
P/S 4.37
EPS this Y 2.08%
Inst Trans 2.72%
Short Ratio 3.27
Perf Half Y 13.32%
Book/sh 36.13
P/B 3.43
EPS next Y 178.58%
ROA -10.38%
Short Interest 5.27M
Perf Year -36.47%
Cash/sh 6.63
P/C 18.69
EPS next 5Y 22.90%
ROE -18.81%
52W Range 89.00 - 213.91
Perf YTD -10.95%
Dividend Est. -
P/FCF 69.87
EPS past 5Y -
ROI -14.66%
52W High -42.04%
Beta 1.24
Dividend TTM -
Quick Ratio 1.29
Sales past 5Y 7.40%
Gross Margin 60.97%
52W Low 39.31%
ATR (14) 4.63
Dividend Ex-Date -
Current Ratio 1.66
EPS Y/Y TTM 73.83%
Oper. Margin -1.62%
RSI (14) 46.94
Volatility 3.27% 3.62%
Employees 12010
Debt/Eq 0.39
Sales Y/Y TTM -1.72%
Profit Margin -25.78%
Recom 2.46
Target Price 151.55
Option/Short Yes / Yes
LT Debt/Eq 0.38
EPS Q/Q -24.92%
Payout -
Rel Volume 0.99
Prev Close 124.68
Sales Surprise 3.19%
EPS Surprise 652.69%
Sales Q/Q 3.60%
Earnings May 02 AMC
Avg Volume 1.61M
Price 123.99
SMA20 -0.05%
SMA50 -5.02%
SMA200 -9.94%
Trades
Volume 1,601,342
Change -0.55%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-16-24 Downgrade
HSBC Securities
Buy → Hold
Jan-04-24 Downgrade
TD Cowen
Outperform → Market Perform
$144
Dec-18-23 Upgrade
Scotiabank
Sector Perform → Sector Outperform
$185
Dec-15-23 Upgrade
Bernstein
Underperform → Mkt Perform
Dec-14-23 Initiated
Stephens
Overweight
$170
Dec-14-23 Initiated
Guggenheim
Buy
$155
Dec-13-23 Initiated
Wolfe Research
Outperform
$175
Dec-12-23 Downgrade
BofA Securities
Neutral → Underperform
$140 → $100
Dec-11-23 Upgrade
Citigroup
Sell → Neutral
$85 → $120
Nov-10-23 Downgrade
Canaccord Genuity
Buy → Hold
$210 → $120
Sep-28-23 Initiated
Bernstein
Underperform
$111
Jul-05-23 Resumed
JP Morgan
Neutral
$235
Jan-25-23 Downgrade
Argus
Buy → Hold
Jan-05-23 Initiated
Scotiabank
Sector Perform
$216
Dec-12-22 Downgrade
Citigroup
Neutral → Sell
$200 → $180
Dec-07-22 Initiated
RBC Capital Mkts
Outperform
$282
Oct-04-22 Upgrade
SVB Leerink
Mkt Perform → Outperform
$220 → $270
Sep-28-22 Upgrade
Evercore ISI
In-line → Outperform
$170 → $250
Aug-25-22 Initiated
Credit Suisse
Neutral
$230
Jul-13-22 Downgrade
Barclays
Equal Weight → Underweight
$350 → $150
Show Previous Ratings
Today 05:35PM
05:21PM
04:17PM
(Associated Press Finance)
04:05PM
06:04AM
09:09PM
Loading…
Apr-29-24 09:09PM
12:45PM
09:16AM
Apr-26-24 06:03AM
Apr-25-24 10:02AM
08:53AM
Apr-21-24 08:30AM
Apr-19-24 02:05PM
12:10PM
Apr-18-24 01:30PM
08:00AM
Loading…
08:00AM
Apr-17-24 09:30AM
Apr-15-24 05:40AM
Apr-12-24 09:00AM
06:21AM
05:49AM
Apr-10-24 08:16AM
Apr-09-24 11:37PM
05:28PM
04:32PM
04:28PM
04:18PM
04:05PM
Apr-05-24 02:27PM
12:45PM
05:00PM
Loading…
Apr-04-24 05:00PM
Apr-02-24 09:45AM
Mar-30-24 07:43PM
Mar-26-24 08:02AM
Mar-25-24 06:17AM
Mar-21-24 06:37PM
05:44AM
05:12AM
05:01AM
Mar-18-24 12:40PM
Mar-17-24 08:50AM
Mar-14-24 07:42PM
Mar-13-24 06:43AM
Mar-12-24 04:50PM
02:41PM
01:57PM
Mar-08-24 08:45AM
Mar-07-24 03:00PM
08:45AM
Mar-02-24 02:30PM
Feb-28-24 05:52AM
Feb-27-24 03:40AM
03:09AM
Feb-26-24 06:29PM
11:00AM
Feb-24-24 06:50AM
Feb-23-24 07:59AM
Feb-21-24 07:42PM
09:00AM
Feb-20-24 10:25AM
Feb-14-24 07:00PM
09:40AM
Feb-09-24 11:19AM
07:52AM
(Thomson Reuters StreetEvents)
07:39AM
05:45AM
01:32AM
Feb-08-24 06:30PM
05:24PM
04:34PM
04:24PM
(Associated Press Finance)
04:05PM
09:14AM
Feb-05-24 09:16AM
Feb-01-24 09:10PM
Jan-30-24 07:31AM
Jan-29-24 07:49PM
Jan-28-24 09:25AM
Jan-23-24 08:45PM
Jan-19-24 08:25AM
Jan-18-24 07:52AM
05:04AM
Jan-17-24 12:04PM
Jan-16-24 10:11AM
Jan-15-24 07:00AM
Jan-12-24 09:45AM
Jan-11-24 09:45AM
Jan-09-24 05:28PM
02:02PM
09:00AM
07:05AM
05:38AM
03:34AM
Jan-08-24 12:45PM
Jan-05-24 09:15AM
Jan-04-24 08:17PM
04:05PM
09:15AM
Dec-28-23 01:02PM
Dec-27-23 10:45AM
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Thaysen Jacob Chief Executive Officer Feb 22 '24 Buy 135.29 7,330 991,672 14,861 Feb 26 08:57 AM Hoyt Aimee L SVP, Chief People Officer Nov 07 '23 Sale 112.84 315 35,545 8,314 Nov 09 04:22 PM TOUSI SUSAN H SVP, Chief Commercial Officer Aug 22 '23 Sale 167.04 500 83,520 45,524 Aug 24 04:19 PM TOUSI SUSAN H SVP, Chief Commercial Officer Jul 24 '23 Sale 190.08 500 95,040 46,022 Jul 26 06:14 PM TOUSI SUSAN H SVP, Chief Commercial Officer Jun 22 '23 Sale 200.00 500 100,000 46,522 Jun 26 05:23 PM EPSTEIN ROBERT S Director May 25 '23 Option Exercise 71.09 7,600 540,284 14,764 May 25 04:34 PM
Index S&P 500
P/E 32.76
EPS (ttm) 4.20
Insider Own 0.41%
Shs Outstand 292.12M
Perf Week 0.84%
Market Cap 40.30B
Forward P/E 22.53
EPS next Y 6.11
Insider Trans -11.59%
Shs Float 291.84M
Perf Month -4.32%
Income 1.24B
PEG 4.07
EPS next Q 1.19
Inst Own 92.85%
Short Float 1.41%
Perf Quarter 3.36%
Sales 6.74B
P/S 5.98
EPS this Y 1.15%
Inst Trans -3.29%
Short Ratio 2.60
Perf Half Y 33.04%
Book/sh 21.12
P/B 6.51
EPS next Y 10.95%
ROA 11.30%
Short Interest 4.12M
Perf Year 2.23%
Cash/sh 5.96
P/C 23.06
EPS next 5Y 8.05%
ROE 20.95%
52W Range 96.80 - 151.58
Perf YTD -1.09%
Dividend Est. 0.94 (0.69%)
P/FCF 24.44
EPS past 5Y 33.93%
ROI 13.95%
52W High -9.28%
Beta 1.09
Dividend TTM 0.92 (0.67%)
Quick Ratio 2.04
Sales past 5Y 7.00%
Gross Margin 54.54%
52W Low 42.07%
ATR (14) 3.45
Dividend Ex-Date Apr 01, 2024
Current Ratio 2.68
EPS Y/Y TTM -5.40%
Oper. Margin 23.91%
RSI (14) 46.13
Volatility 2.29% 2.39%
Employees 18100
Debt/Eq 0.44
Sales Y/Y TTM -2.81%
Profit Margin 18.35%
Recom 2.33
Target Price 150.54
Option/Short Yes / Yes
LT Debt/Eq 0.43
EPS Q/Q -0.13%
Payout 21.48%
Rel Volume 0.72
Prev Close 138.69
Sales Surprise 4.45%
EPS Surprise 5.31%
Sales Q/Q -5.58%
Earnings Apr 18 AMC
Avg Volume 1.58M
Price 137.52
SMA20 -1.21%
SMA50 -2.89%
SMA200 8.17%
Trades
Volume 1,146,811
Change -0.84%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-05-24 Upgrade
Stifel
Hold → Buy
$145 → $163
Dec-13-23 Initiated
Wolfe Research
Outperform
$140
Dec-12-23 Downgrade
BofA Securities
Buy → Neutral
$130 → $133
Nov-17-23 Downgrade
UBS
Buy → Neutral
$163 → $125
Sep-28-23 Initiated
Bernstein
Mkt Perform
$123
Jul-31-23 Downgrade
Evercore ISI
Outperform → In-line
$126 → $124
May-24-23 Reiterated
Wells Fargo
Overweight
$170 → $160
May-24-23 Reiterated
TD Cowen
Outperform
$168 → $145
May-24-23 Reiterated
SVB Securities
Outperform
$170 → $145
May-24-23 Reiterated
Stifel
Hold
$153 → $135
May-24-23 Reiterated
Robert W. Baird
Outperform
$174 → $144
May-24-23 Reiterated
Evercore ISI
Outperform
$150 → $126
May-24-23 Reiterated
Credit Suisse
Outperform
$170 → $160
May-24-23 Reiterated
Citigroup
Neutral
$150 → $130
May-24-23 Reiterated
BofA Securities
Buy
$164 → $144
May-24-23 Reiterated
Barclays
Equal Weight
$140 → $135
May-24-23 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
May-11-23 Initiated
Barclays
Equal Weight
$140
Jan-10-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$170
Aug-25-22 Initiated
Credit Suisse
Outperform
$165
Show Previous Ratings
Today 04:53PM
12:10PM
11:45AM
09:30AM
May-01-24 10:31AM
08:45AM
Loading…
08:45AM
08:00AM
Apr-29-24 08:45AM
Apr-18-24 04:30PM
Apr-16-24 08:00AM
Apr-15-24 08:00AM
Apr-09-24 11:37PM
12:02PM
10:41AM
Apr-05-24 09:55AM
08:00AM
Loading…
Apr-04-24 08:00AM
Apr-03-24 08:00AM
Apr-02-24 11:15AM
08:00AM
Apr-01-24 08:00AM
Mar-29-24 09:30AM
Mar-28-24 11:30AM
Mar-27-24 05:01PM
Mar-26-24 02:00AM
Mar-14-24 08:00AM
Mar-12-24 05:00PM
Mar-06-24 09:30AM
12:01AM
Mar-05-24 02:21PM
(Investor's Business Daily)
Mar-04-24 07:45PM
08:00AM
Loading…
Feb-29-24 08:00AM
Feb-28-24 04:21PM
12:53PM
10:03AM
09:36AM
09:21AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-27-24 09:27PM
06:58PM
06:00PM
05:20PM
04:32PM
04:15PM
(Associated Press Finance)
04:05PM
Feb-26-24 12:23PM
Feb-22-24 11:33AM
09:15AM
05:12AM
Feb-21-24 04:45PM
04:25PM
04:20PM
04:12PM
Feb-20-24 06:15PM
Feb-14-24 06:15PM
Feb-13-24 10:11AM
Feb-08-24 06:15PM
08:00AM
Feb-07-24 11:20AM
Feb-05-24 06:30AM
Feb-02-24 06:15PM
06:27AM
Jan-31-24 07:00AM
Jan-30-24 11:07AM
08:00AM
Jan-29-24 09:26AM
Jan-26-24 06:15PM
Jan-25-24 12:29PM
Jan-22-24 03:35PM
Jan-17-24 12:58PM
Jan-16-24 08:00AM
Jan-09-24 05:21AM
Jan-05-24 10:29AM
Dec-28-23 08:51PM
Dec-22-23 05:23AM
Dec-21-23 01:02AM
Dec-20-23 11:30AM
08:58AM
Dec-18-23 10:01AM
Dec-16-23 07:01AM
Dec-14-23 03:17PM
Dec-09-23 03:05AM
Dec-07-23 09:46AM
08:00AM
Dec-06-23 02:46AM
Dec-04-23 08:00AM
Nov-21-23 05:12PM
04:14PM
03:42PM
01:20PM
12:35PM
12:12PM
12:00PM
11:08AM
10:02AM
(Thomson Reuters StreetEvents)
07:33AM
Nov-20-23 07:28PM
06:00PM
04:41PM
04:22PM
(Associated Press Finance)
04:05PM
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Binns Philip Senior Vice President Mar 25 '24 Sale 147.54 2,827 417,096 9,997 Mar 27 01:29 PM McMullen Michael R. CEO and President Mar 08 '24 Sale 150.00 52,297 7,844,550 253,909 Mar 12 02:37 PM Gonsalves Rodney V.P., Corporate Controller Mar 07 '24 Sale 149.00 4,828 719,348 21,329 Mar 08 12:05 PM FIELDS HEIDI Director Mar 05 '24 Sale 144.34 1,658 239,316 54,976 Mar 07 10:38 AM Binns Philip Senior Vice President Dec 27 '23 Sale 139.78 2,880 402,566 12,824 Dec 28 01:46 PM Gonsalves Rodney V.P., Corporate Controller Dec 18 '23 Sale 137.69 1,500 206,538 26,133 Dec 19 02:34 PM Ancher-Jensen Henrik Sr Vice President Dec 15 '23 Option Exercise 111.36 11,703 1,303,235 108,835 Dec 19 02:33 PM Ancher-Jensen Henrik Sr Vice President Dec 15 '23 Sale 138.36 26,331 3,643,157 82,504 Dec 19 02:33 PM McMullen Michael R. CEO and President Dec 13 '23 Option Exercise 42.12 2,751 115,872 308,957 Dec 15 05:08 PM McMullen Michael R. CEO and President Dec 13 '23 Sale 130.00 2,751 357,630 306,206 Dec 15 05:08 PM McMullen Michael R. CEO and President Dec 07 '23 Option Exercise 42.12 62,467 2,631,110 368,673 Dec 08 02:59 PM McMullen Michael R. CEO and President Dec 07 '23 Sale 130.00 62,467 8,120,710 306,206 Dec 08 02:59 PM Gonsalves Rodney V.P., Corporate Controller Sep 28 '23 Buy 111.09 3 288 24,222 Sep 29 04:03 PM Gonsalves Rodney V.P., Corporate Controller Aug 23 '23 Sale 118.78 3,500 415,716 24,219 Aug 25 12:53 PM McMullen Michael R. CEO and President Jul 27 '23 Option Exercise 42.12 944 39,761 261,813 Jul 31 03:03 PM McMullen Michael R. CEO and President Jul 27 '23 Sale 130.00 944 122,720 260,869 Jul 31 03:03 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite